Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake

As Company’s Biosimilars Turnover Grows By Over 80% In Q1

Executive Summary

Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled. 

You may also be interested in...



Pfizer And J&J Settle Remicade Antitrust Litigation

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel